ClinicalTrials.gg
Active, not recruitingNCT05535946Updated Jul 7, 2026

ABTECT - Maintenance

A Phase 3 interventional study of ABX464 and Placebo in Ulcerative Colitis, sponsored by Abivax S.A.. Active, not recruiting at 413 sites in 34 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Abivax S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,116
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Enrollment
17th of 499
1,116 · median 76
Started
2023
with 34 others
Phase 3
116 of 615
15 open now
Primary completion
2026-04
later than 31 of 165 live
Registered
467th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 17th largest by enrollment of the 499 interventional ones that give a count, is one of 35 that started in 2023, is one of 116 in phase 3, reaches primary completion later than 31 of the 165 other live ones, and was the 467th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].

This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.

Read the detailed description

All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 study which consists of 2 treatment phases.

This study consists of a 44-week maintenance treatment phase (Part 1 and Part 2), followed by a 4-year Long Term Extension (LTE) treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.

The maintenance phase is a 44-week double blind, placebo-controlled, phase. Subjects who are clinical responders after 8 weeks induction will be randomized to Part 1, and those who are non-clinical responders will be randomized to Part 2.

At the end of the 44-week maintenance phase, subjects will continue their allocated treatment until the maintenance phase is unblinded.

Once the study is unblinded, all subjects receiving obefazimod will continue their allocated treatment. Subjects receiving placebo will be allocated to obefazimod 25 mg or can terminate the study.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria in maintenance phase:

  • Subjects must have completed the induction treatment study (ABX464-105 or ABX464-106), and patients' clinical response status must be available.
  • Subjects with a valid endoscopy performed at the end of the induction study and results from central reader available at Day 1.
  • Subjects must understand, sign and date the written voluntary form at the visit prior to any protocol-specific procedures. For under-aged subjects, national requirements regarding consent should also be met.
  • Women of (WOCBP) subjects and male subjects with WOCBP partner must agree to comply with requirements as described in Section 4.4. (Contraception) of the protocol.
  • Subjects must be able and willing to comply with study visits and procedures as per protocol.
  • Subjects should be affiliated to a health insurance policy whenever required by a participating country or state

Inclusion criteria in LTE phase:

  • Subject must have completed the maintenance phase
  • Investigator and subject must assess and agree that the subject has received, and will continue to receive benefit from being in the study

Exclusion Criteria in maintenance phase:

  • Subjects who permanently discontinued the study treatment during the induction study (either ABX464-105 or ABX464-106).
  • Subjects who have developed any major illness/condition (eg. primary sclerosis cholangitis, Crohn's disease, colectomy, diverting ileostomy, colon cancer or colonic adenomas [low or high grade dysplasia]).
  • Subjects with evidence of an unstable clinical condition (eg. toxic megacolon, fulminant colitis, bowel perforation, uncontrolled ischemic disease, congestive heart failure with class 3 or 4 symptoms) during the induction study that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.
  • Subjects who plan to participate in other studies during the maintenance study.
  • Male or female planning a pregnancy, or pregnant female subjects
  • Introduction during induction study of prohibited medications, dosages, surgical or non-medicinal procedures indicated for UC (except antidiarrheals and motility agents for acute diarrhea).
  • Any changes in the laboratory values during the induction period that could jeopardize subject's safety in the opinion of the investigator. If any doubts, the investigator should contact the sponsor study medical monitor.
  • Subject who is planning to receive during the study.
  • Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.

Exclusion criteria for LTE phase:

  • Subject continues to satisfy exclusion criteria listed above for the maintenance phase
  • Introduction during maintenance phase of prohibited medications, dosages, surgical or non-medicinal procedures indicated for UC (except antidiarrheals and motility agents for acute diarrhea).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,116 participants (actual)

Study arms

  • Placebo comparator
    ABX464 50mg - Responder subjects at the end of induction

    Subjects will be orally dosed during 44 weeks

    Drug: ABX464

  • Placebo comparator
    ABX464 25mg - Responder subjects at the end of induction

    Subjects will be orally dosed during 44 weeks

    Drug: ABX464

  • Placebo comparator
    Placebo - Responder subjects at the end of induction

    Subjects will be orally dosed during 44 weeks

    Drug: Placebo

  • Experimental
    ABX464 50mg - Non responder subjects at the end of induction

    Subjects will be orally dosed during 44 weeks

    Drug: ABX464

  • Experimental
    ABX464 25mg - Non responder subjects at the end of induction

    Subjects will be orally dosed during 44 weeks

    Drug: ABX464

  • Experimental
    Long Term Extension

    At the end of the maintenance phase (week 44), subjects can continue their allocated treatment for up to 4 years. Once the maintenance phase is unblinded, subjects receiving placebo in the maintenance phase will be allocated to obefazimod 25 mg or can terminate the study.

    Drug: ABX464

Interventions

  • DrugABX464

    Administered once daily, preferably in the morning, with food

    Also known as: Obefazimod

  • DrugPlacebo

    Administered once daily, preferably in the morning, with food

06

What researchers measure

Primary outcomes

  1. Rate of subjects in clinical remission at Week 44

    The Part 1 primary objective is to compare the efficacy of ABX464 versus placebo on the proportion of subjects in clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Week 44.

    Time frame: Week 44

  2. Number and percentage of all treatment-emergent adverse events (TEAEs)

    The Part 2 primary objective is safety

    Time frame: Week 44

  3. Number and percentage of all serious adverse events (SAEs)

    The Part 2 primary objective is safety

    Time frame: Week 44

  4. Number and percentage of all causally related TEAEs/SAEs

    The Part 2 primary objective is safety

    Time frame: Week 44

Secondary outcomes

  1. Proportion of subjects with endoscopic improvement at Week 44

    To compare the efficacy of ABX464 versus placebo on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1) at Week 44

    Time frame: Week 44

  2. Proportion of subjects with corticosteroid-free clinical remission

    To compare the efficacy of ABX464 versus placebo on corticosteroid-free clinical remission (clinical remission at Week 44 and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry)

    Time frame: Week 44

  3. Proportion of subjects with sustained clinical remission at Week 44

    To compare the efficacy of ABX464 versus placebo to sustain clinical remission at Week 44

    Time frame: Week 44

  4. Proportion of subjects with HEMI per Geboes scoring at Week 44

    To evaluate the efficacy of ABX464 on histologic-endoscopic mucosal improvement (HEMI) versus placebo at Week 44

    Time frame: Week 44

  5. Proportion of subjects with endoscopic remission at Week 44

    To compare the efficacy of ABX464 versus placebo on endoscopic remission (MES = 0) at Week 44

    Time frame: Week 44

  6. LTE Phase - Proportion of subjects in clinical remission at Year 1

    To evaluate the efficacy of obefazimod on clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Year 1

    Time frame: LTE Year 1

  7. LTE Phase - Proportion of subjects in clinical remission at Year 4

    To evaluate the efficacy of obefazimod on clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Year 4

    Time frame: LTE Year 4

  8. LTE Phase - Proportion of subjects with corticosteroid-free clinical remission in the subpopulation with corticosteroids at maintenance study entry

    To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 1 and corticosteroid free for at least 12 weeks prior to Year 1 in the subpopulation with corticosteroids at maintenance study entry)

    Time frame: LTE Year 1

  9. LTE Phase - Proportion of subjects with corticosteroid-free clinical remission in the subpopulation with corticosteroids at maintenance study entry)

    To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 4 and corticosteroid free for at least 12 weeks prior to Year 4 in the subpopulation with corticosteroids at maintenance study entry)

    Time frame: LTE Year 4

  10. LTE Phase - Proportion of subjects with endoscopic improvement at LTE Year 1

    To evaluate the efficacy of obefazimod on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1)

    Time frame: LTE Year 1

  11. LTE Phase - Proportion of subjects with endoscopic improvement at LTE Year 4

    To evaluate the efficacy of obefazimod on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1)

    Time frame: LTE Year 4

  12. LTE Phase - Proportion of subjects with endoscopic remission at LTE year 1

    To evaluate the efficacy of obefazimod on endoscopic remission ((Mayo Endoscopic Subscore (MES) = 0)

    Time frame: LTE year 1

  13. LTE Phase - Proportion of subjects with endoscopic remission at LTE year 4

    To evaluate the efficacy of obefazimod on endoscopic remission (Mayo Endoscopic Subscore (MES) = 0)

    Time frame: LTE year 4

  14. LTE Phase - Proportion of subjects with CS-free symptomatic remission by visit

    To evaluate the efficacy of obefazimod on CS-free symptomatic remission (symptomatic remission (SFS = 0 or 1 and RBS = 0) and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry) by visit (every 3-month)

    Time frame: 4 years

  15. LTE Phase - Proportion of subjects with HEMI per Geboes scoring at LTE Year 1

    To evaluate the efficacy of obefazimod on histologic endoscopic mucosal improvement (HEMI) per Geboes scoring

    Time frame: LTE Year 1

  16. LTE Phase - Proportion of subjects with HEMI per Geboes scoring at LTE Year 4

    To evaluate the efficacy of obefazimod on histologic endoscopic mucosal improvement (HEMI) per Geboes scoring

    Time frame: LTE Year 4

  17. LTE Phase - Proportion of subjects with HEMR per Geboes scoring at LTE Year 1

    To evaluate the efficacy of obefazimod on histologic endoscopic mucosal remission (HEMR) versus placebo

    Time frame: LTE Year 1

  18. LTE Phase - Proportion of subjects with HEMR per Geboes scoring at LTE Year 4

    To evaluate the efficacy of obefazimod on histologic endoscopic mucosal remission (HEMR) versus placebo

    Time frame: LTE Year 4

  19. LTE Phase - Proportion of subjects with sustained clinical remission at LTE Year 1, in the sub-population of subjects with clinical remission at Week 44

    To evaluate the efficacy of obefazimod on sustained clinical remission Sustained clinical remission for the LTE is defined as clinical remission assessed at an endoscopy visit during the LTE in the sub-population of subjects in clinical remission at Week 44.

    Time frame: LTE Year 1

  20. LTE Phase - Proportion of subjects with sustained clinical remission at LTE year 4, in the sub-population of subjects with clinical remission at Week 44

    To evaluate the efficacy of obefazimod on sustained clinical remission Sustained clinical remission for the LTE is defined as clinical remission assessed at an endoscopy visit during the LTE in the sub-population of subjects in clinical remission at Week 44.

    Time frame: LTE year 4

  21. LTE Phase - Proportion of subjects with sustained endoscopic improvement at LTE Year 1, in the sub-population of subjects with endoscopic improvement at Week 44

    To evaluate the efficacy of obefazimod on sustained endoscopic improvement

    Time frame: LTE Year 1

  22. LTE Phase - Proportion of subjects with sustained endoscopic improvement at LTE Year 4, in the sub-population of subjects with endoscopic improvement at Week 44

    To evaluate the efficacy of obefazimod on sustained endoscopic improvement

    Time frame: LTE year 4

  23. LTE Phase - Proportion of subjects with symptomatic remission by visit

    To evaluate the efficacy of obefazimod on symptomatic remission (SFS = 0 or 1 and RBS = 0) by visit (every 3-month)

    Time frame: 4 years

  24. LTE Phase - Proportion of subjects with sustained symptomatic remission by visit

    To evaluate the efficacy of obefazimod on sustained symptomatic remission (SFS = 0 or 1 and RBS = 0) by visit (every 3-month), in the sub-population of subjects with symptomatic remission at Week 44

    Time frame: 4 years

  25. LTE Phase - Proportion of subjects with CS-free clinical remission at LTE Year 1

    To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 1 and CS-free for at least 12 weeks immediately prior to Year 1)

    Time frame: LTE Year 1

  26. LTE Phase - Proportion of subjects with CS-free clinical remission at LTE Year 4

    To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 4 and CS-free for at least 12 weeks immediately prior to Year 4)

    Time frame: LTE Year 4

07

Study locations

413 sites

Showing the first 100 of 413 sites across 34 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Apr 2026, 39 months.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 39 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2022
First posted
Sep 10, 2022
StartActual
Jan 16, 2023
Primary completionActual
Apr 28, 2026
CompletionEst.
May 2030
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05535946
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Sep 10, 2022
Start date
Jan 16, 2023
Primary completion
Apr 28, 2026
Completion
May 2030 (estimated)
Last update
Jul 7, 2026

Study contacts

Severine Vermeire, MD, PhD
principal investigator · UZ Leuven, Belgium
Bruce Sands, MD, PhD
principal investigator · Mount Sinai Health System Digestive Disease Institute, New York USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion